More than meets the eye: the ocular toxicities accessory to anticancer therapies
Future Oncology · 01.01.2023 · 19 (3) · 189-191
DOI: 10.2217/fon-2022-0825 ↗Kurz gefasst
Editorial in der Zeitschrift Future Oncology, online erschienen am 09.03.2023. Verfasst von Blake H Fortes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Cancer is the second leading cause of death in the United States with over 1.9 million new cancer cases and 609,000 deaths estimated to occur in this country alone in 2022 [1]. As a result, cancer ...
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
ORCID-Profile: Blake H Fortes, Prashant D Tailor, Lauren A Dalvin
Förderung
- NCATS NIH HHS
- NCI NIH HHS
- National Cancer Institute
- Leonard and Mary Lou Hoeft Career Development Award Fund in Ophthalmology Research
- National Center for Advancing Translational Sciences
Zitieren
APA
Fortes, B. H., Tailor, P. D., & Dalvin, L. A. (2023). More than meets the eye: the ocular toxicities accessory to anticancer therapies. Future Oncology, 19(3), 189-191. https://doi.org/10.2217/fon-2022-0825
Vancouver
Fortes BH, Tailor PD, Dalvin LA. More than meets the eye: the ocular toxicities accessory to anticancer therapies. Future Oncology. 2023;19(3):189-191. doi:10.2217/fon-2022-0825
BibTeX
@article{Fortes2023,
author = {Fortes, Blake H and Tailor, Prashant D and Dalvin, Lauren A},
title = {More than meets the eye: the ocular toxicities accessory to anticancer therapies},
journal = {Future Oncology},
year = {2023},
volume = {19},
number = {3},
pages = {189--191},
doi = {10.2217/fon-2022-0825}
}
EUVIMED